



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PF-05214030

| | | | |
|---------------------------|--|-------|----------|
| Cat. No.: | HY-160603 | | |
| CAS No.: | 1669444-50-1 | | |
| Molecular Formula: | C ₁₇ H ₁₃ Cl ₂ FN ₂ O ₄ S | | |
| Molecular Weight: | 431.27 | | |
| Target: | TRP Channel | | |
| Pathway: | Membrane Transporter/Ion Channel; Neuronal Signaling | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 200 mg/mL (463.75 mM; Need ultrasonic)

| Concentration | Solvent | Mass | | |
|---------------------------|---------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 2.3187 mL | 11.5937 mL | 23.1873 mL |
| | 5 mM | 0.4637 mL | 2.3187 mL | 4.6375 mL |
| | 10 mM | 0.2319 mL | 1.1594 mL | 2.3187 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PF-05214030 is a TRPV4 antagonist (IC₅₀: 4 and 27nM for hTRPV4 and rTRPV4 respectively). PF-05214030 reverses the reduction in bladder capacity caused by intravesical infusion of a TRPV4 agonist^{[1][2]}.

REFERENCES

- [1]. Jiang Y, et al. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. *J Hematol Oncol.* 2022 Mar 24;15(1):34.
- [2]. Sarah Skerratt, et al. The Discovery and Optimisation of a Highly Selective Series of TRPV4 Antagonists.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA